HK1028560A1 - Use of herpes vectors for tumor therapy - Google Patents

Use of herpes vectors for tumor therapy

Info

Publication number
HK1028560A1
HK1028560A1 HK00107700A HK00107700A HK1028560A1 HK 1028560 A1 HK1028560 A1 HK 1028560A1 HK 00107700 A HK00107700 A HK 00107700A HK 00107700 A HK00107700 A HK 00107700A HK 1028560 A1 HK1028560 A1 HK 1028560A1
Authority
HK
Hong Kong
Prior art keywords
tumor
cells
patient
immune response
cell type
Prior art date
Application number
HK00107700A
Other languages
English (en)
Inventor
Samuel D Rabkin
Masahiro Toda
Robert L Martuza
Original Assignee
Univ Georgetown
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26733894&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1028560(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Georgetown filed Critical Univ Georgetown
Publication of HK1028560A1 publication Critical patent/HK1028560A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK00107700A 1997-08-12 2000-11-30 Use of herpes vectors for tumor therapy HK1028560A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5514297P 1997-08-12 1997-08-12
US09/064,174 US6379674B1 (en) 1997-08-12 1998-04-22 Use of herpes vectors for tumor therapy
PCT/US1998/016447 WO1999007394A1 (en) 1997-08-12 1998-08-12 Use of herpes vectors for tumor therapy

Publications (1)

Publication Number Publication Date
HK1028560A1 true HK1028560A1 (en) 2001-02-23

Family

ID=26733894

Family Applications (1)

Application Number Title Priority Date Filing Date
HK00107700A HK1028560A1 (en) 1997-08-12 2000-11-30 Use of herpes vectors for tumor therapy

Country Status (12)

Country Link
US (5) US6379674B1 (de)
EP (2) EP1003533B1 (de)
JP (2) JP5078195B2 (de)
AT (1) ATE342724T1 (de)
AU (1) AU8824998A (de)
CA (1) CA2301327C (de)
DE (1) DE69836219T2 (de)
ES (2) ES2627764T3 (de)
HK (1) HK1028560A1 (de)
LU (1) LUC00032I2 (de)
PT (1) PT1776957T (de)
WO (1) WO1999007394A1 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6379674B1 (en) * 1997-08-12 2002-04-30 Georgetown University Use of herpes vectors for tumor therapy
WO2000040734A1 (en) * 1998-12-31 2000-07-13 Arch Development Corporation Recombinant herpes simplex virus useful for treating neoplastic disease
AU6120600A (en) * 1999-06-08 2000-12-28 Uab Research Foundation Herpes simplex virus expressing foreign genes and method for treating cancers therewith
US6764675B1 (en) 1999-06-08 2004-07-20 The Uab Research Foundation Herpes simplex virus expressing foreign genes and method for treating cancers therewith
AU2584901A (en) * 1999-12-22 2001-07-03 Onyx Pharmaceuticals, Inc. Herpes simplex virus-1 glycoprotein c mutants for treating unwanted hyperproliferative cell growth
WO2001053506A2 (en) 2000-01-21 2001-07-26 Biovex Limited Virus strains for the oncolytic treatment of cancer
ES2366608T3 (es) 2001-03-27 2011-10-21 The General Hospital Corporation Vectores víricos y su uso en métodos terapéuticos.
WO2002087625A1 (en) * 2001-05-02 2002-11-07 Ramot At Tel-Aviv University Ltd. Composite oncolytic herpes virus vectors
DE10131148A1 (de) * 2001-06-28 2003-01-16 I P L Internat Pharmaceutics L Xenogene Oligo- oder/und Polyribonukleotide als Mittel zur Behandlung von malignen Tumoren
AU2003216502B2 (en) * 2002-03-01 2008-04-10 Sloan-Kettering Institute For Cancer Research Prevention of recurrence and metastasis of cancer
US8216564B2 (en) * 2002-05-02 2012-07-10 Ramot At Tel-Aviv University Ltd. Composite oncolytic herpes virus vectors
JP2004099584A (ja) * 2002-05-02 2004-04-02 Keio Gijuku Ｈｓｖを用いた抗腫瘍剤
ES2463442T3 (es) 2004-03-31 2014-05-28 Tomoki Todo Potenciador de la actividad anticancerosa en terapia viral y método de prevención o de tratamiento del cáncer
WO2006002394A2 (en) 2004-06-24 2006-01-05 New York University Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
US8450106B2 (en) * 2007-10-17 2013-05-28 The Ohio State University Research Foundation Oncolytic virus
WO2009052426A2 (en) * 2007-10-17 2009-04-23 The Ohio State University Oncolytic virus
KR100905419B1 (ko) 2008-09-11 2009-07-02 연세대학교 산학협력단 세스퀴테르펜 유도체의 용도
WO2010054379A2 (en) 2008-11-10 2010-05-14 The United States Of America, As Represensted By The Secretary, Department Of Health And Human Services Gene signature for predicting prognosis of patients with solid tumors
US9150926B2 (en) 2010-12-06 2015-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Diagnosis and treatment of adrenocortical tumors using human microRNA-483
WO2013036795A2 (en) 2011-09-08 2013-03-14 New York University Oncolytic herpes simplex virus and therapeutic uses thereof
MA40948A (fr) 2014-12-18 2017-10-25 Amgen Inc Formulation de virus de l'herpès simplex congelée stable
WO2016205429A1 (en) 2015-06-15 2016-12-22 New York University Method of treatment using oncolytic viruses
WO2017013419A1 (en) 2015-07-20 2017-01-26 Virttu Biologics Limited Use of oncolytic herpes simplex virus, alone or in combination with immune checkpoint inhibitor, in the treatment of cancer
EP3805376A1 (de) 2016-01-08 2021-04-14 Replimune Limited Manipulierter virus
US10888594B2 (en) 2016-05-30 2021-01-12 National University Corporation Tottori University Genetically engineered vaccinia viruses
BR112018074881A2 (pt) * 2016-05-30 2019-03-26 National University Corporation Tottori University novos vírus vaccinia geneticamente modificados
US20190336552A1 (en) 2016-05-30 2019-11-07 Astellas Pharma Inc. Genetically engineered vaccinia viruses
ES2972406T3 (es) * 2016-08-01 2024-06-12 Virogin Biotech Canada Ltd Vectores del virus oncolítico del herpes simple que expresan moléculas estimuladoras del sistema inmunitario
GB201700350D0 (en) 2017-01-09 2017-02-22 Replimune Ltd Altered virus
CA3056392A1 (en) 2017-03-15 2018-09-20 Amgen Inc. Use of oncolytic viruses, alone or in combination with a checkpoint inhibitor, for the treatment of cancer
KR102414120B1 (ko) 2017-08-03 2022-06-28 암젠 인크 인터류킨-21 뮤테인 및 치료 방법
MX2020001451A (es) 2017-08-07 2020-08-06 Amgen Inc Tratamiento de cancer de mama triple negativo o cancer colorrectal con metastasis hepaticas con un anticuerpo anti-pd-l1 y un virus oncolitico.
CN116003405A (zh) 2017-09-08 2023-04-25 美国安进公司 Kras g12c的抑制剂及其使用方法
SG11202005605SA (en) 2018-01-12 2020-07-29 Amgen Inc Anti-pd-1 antibodies and methods of treatment
CN108635380A (zh) * 2018-04-13 2018-10-12 北京唯源立康生物科技有限公司 重组溶瘤病毒组合物及其在制备用于治疗肿瘤的药物中的应用
US11638730B2 (en) 2018-09-26 2023-05-02 Astellas Pharma Inc. Cancer therapy by combination use of oncolytic vaccinia virus and immune checkpoint inhibitor, and pharmaceutical composition and combination medicine for use in the cancer therapy
WO2020140012A1 (en) 2018-12-27 2020-07-02 Amgen Inc. Lyophilized virus formulations
AU2020232264A1 (en) 2019-03-05 2021-08-26 Amgen Inc. Use of oncolytic viruses for the treatment of cancer
TW202102543A (zh) 2019-03-29 2021-01-16 美商安進公司 溶瘤病毒在癌症新輔助療法中之用途
KR20230166118A (ko) * 2021-04-02 2023-12-06 크리스탈 바이오테크, 인크. 암 요법을 위한 바이러스 벡터

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9001828A (nl) 1990-08-15 1992-03-02 Centraal Diergeneeskundig Inst Werkwijze voor het wijzigen van het cel-, weefsel- of gastheertropisme van een microoerganisme; aldus verkregen gerecombineerd microorganisme en toepassing daarvan in de geneeskunde en diergeneeskunde.
WO1992014821A2 (en) 1990-10-25 1992-09-03 Massachusetts Institute Of Technology Nestin expression as an indicator of neuroepithelial tumors
DE69332525T2 (de) * 1992-03-31 2003-04-17 Arch Development Corp., Chicago Behandlung von Tumorerkrankungen mit modifiziertem HSV
US5639656A (en) * 1994-03-31 1997-06-17 Medical College Of Hampton Road Antibodies reactive with biological markers of benign prostate hyperplasia
US5571515A (en) 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
US5585096A (en) 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
US6699468B1 (en) * 1994-06-23 2004-03-02 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
US5728379A (en) 1994-06-23 1998-03-17 Georgetown University Tumor- or cell-specific herpes simplex virus replication
JP3822261B2 (ja) * 1994-09-09 2006-09-13 財団法人癌研究会 癌の遺伝子治療剤
GB9511101D0 (en) 1995-06-01 1995-07-26 British Tech Group Magnetic coil
EP1314430A1 (de) * 1996-01-25 2003-05-28 The University Court Of The University Of Glasgow Behandlung von nicht-neuronalen Krebs durch Verwendung eines HSV Mutants
US6051428A (en) * 1997-03-21 2000-04-18 Sloan-Kettering Institute For Cancer Research Rapid production of autologous tumor vaccines
US6379674B1 (en) * 1997-08-12 2002-04-30 Georgetown University Use of herpes vectors for tumor therapy
ES2366608T3 (es) * 2001-03-27 2011-10-21 The General Hospital Corporation Vectores víricos y su uso en métodos terapéuticos.

Also Published As

Publication number Publication date
ES2627764T3 (es) 2017-07-31
CA2301327A1 (en) 1999-02-18
EP1776957B1 (de) 2017-03-01
DE69836219D1 (de) 2006-11-30
EP1776957A3 (de) 2009-06-24
US20090053178A1 (en) 2009-02-26
US8361978B2 (en) 2013-01-29
JP2001513508A (ja) 2001-09-04
US9827307B2 (en) 2017-11-28
CA2301327C (en) 2011-06-14
LUC00032I1 (de) 2017-08-10
JP5078195B2 (ja) 2012-11-21
AU8824998A (en) 1999-03-01
ES2276470T3 (es) 2007-06-16
LUC00032I2 (de) 2017-10-11
EP1776957A2 (de) 2007-04-25
EP1003533A1 (de) 2000-05-31
US6379674B1 (en) 2002-04-30
US20020127246A1 (en) 2002-09-12
PT1776957T (pt) 2017-06-12
EP1003533B1 (de) 2006-10-18
DE69836219T2 (de) 2007-08-23
WO1999007394A1 (en) 1999-02-18
US20050232907A1 (en) 2005-10-20
ATE342724T1 (de) 2006-11-15
JP2012067114A (ja) 2012-04-05
US20130224243A1 (en) 2013-08-29

Similar Documents

Publication Publication Date Title
LUC00032I1 (de)
Vikan Art, medicine, and magic in early Byzantium
EP0584266A4 (de) Karcinoembryonale antigen expremierende rekombinante viren und methoden ihrer anwendung.
CZ63995A3 (en) Virus vectors and their use in gene therapy
ZA949104B (en) Recombinant viruses and their use in gene therapy
WO1996003997A3 (en) Treatment of cancer using hsv mutant
EP0623020A4 (de) Pyropheophorbide und ihre verwendung in der photodynamischen therapie.
BRPI0107737B1 (pt) vírus do herpes simplex 1 (hsv1), uso do hsv1, e, composição farmacêutica
AU4283389A (en) Modified viral glycoproteins, diagnostic and therapeutic uses therefore
GB9415167D0 (en) Improvements relating to cancer therapy
HK24595A (en) Reduction of side effects of cancer therapy
FR2718150B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
AU2905199A (en) Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
FR2712602B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
AU1927797A (en) Vectors based on recombinant defective viral genomes, and their use in the formulation of vaccines
ZA941426B (en) Recombinant viruses and their use in gene therapy
GR3031354T3 (en) Soluble interferon -receptor, its preparation and use.
GB9601640D0 (en) Ligand directed enzyme prodrug therapy
EP0876507A4 (de) Regelung und kontrolle der expression der protein phosphatase 2c-pp2c-alpha in tumor zellen bei der tumor therapie, vorbeugung und bestimmung
FR2717495B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
IL112992A0 (en) Recombinant viruses, their preparation and their use in gene therapy
EP0828005A3 (de) Apoptotische Mittel für Tumorzellen des Nervensystems
FR2717823B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
IL112994A0 (en) Recombinant viruses, their preparation and their use in gene therapy
MY105075A (en) Cancer treatment

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20180811